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Abstract: Background: Genome-wide association studies (GWAS) found that IGF2BP2 rs4402960 and
rs1470579 polymorphisms were associated with type 2 diabetes mellitus (T2DM) risk. Many studies
have replicated this association, but yielded inconsistent results. Materials and Methods: A case-control
study consisting of 461 T2DM patients and 434 health controls was conducted to detect the genetic
susceptibility of IGF2BP2 in a northern Han Chinese population. A meta-analysis was to evaluate
the association more precisely in Asians. Results: In the case-control study, the carriers of TT
genotype at rs4402960 had a higher T2DM risk than the G carriers (TG + GG) (adjusted odd ratio
(AOR) = 1.962, 95% confidence interval (95% CI) = 1.065–3.612, p = 0.031]; CC carriers at rs1470579
were more susceptible to T2DM than A carriers (CA + AA) (AOR = 2.014, 95% CI = 1.114–3.642,
p = 0.021). The meta-analysis containing 36 studies demonstrated that the two polymorphisms
were associated with T2DM under the allele comparison, genetic models of dominant and recessive
in Asians (p < 0.05). The rs4402960 polymorphisms were significantly associated with the T2DM
risk after stratification by diagnostic criterion, size of sample and average age and BMI of cases,
while there’re no consistent results for rs1470579. Conclusions: Our data suggests that IGF2BP2
polymorphisms are associated with T2DM in Asian populations.
Keywords: type 2 diabetes mellitus; IGF2BP2; case-control study; meta-analysis; Asian
1. Introduction
The rapidly increasing prevalence of type 2 diabetes mellitus (T2DM) is identified as a major
international health concern, with a great impact on global morbidity and premature mortality, not
to mention the pressure on society and the economy of its chronic complications [1]. In China, the
prevalence of diabetes increased from 0.9% in 1980 to 11.6% in 2013, suggesting that there were
approximately 113.9 million Chinese adults suffering from diabetes [2].
T2DM is a complex metabolic syndrome with a strong genetic component, which plays a role in the
initiation and development of T2DM [3,4]. Over the past several years, the genome-wide association
studies (GWAS) have identified approximately 40 susceptibility loci [5]. Since the association of the
gene insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) and risk of T2DM was founded
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by the study group of the Wellcome Trust Case Control Consortium (WTCCC), IGF2BP2 has been
identified as a notable T2DM candidate gene [6–8].
IGF2BP2 is located on chromosome 3q27 [7]. IGF2BP2, highly expressed in pancreatic islets,
belongs to a family of the insulin-like growth factor 2 (IGF2) mRNA-binding proteins, which play
roles in normal embryonic growth and development [9]. Moreover, IGF2BP2 has been found to be
associated with decreased insulin secretion, which plays a role in T2DM [10]. Duesing et al. stated that
rs4402960 and rs1470579 of IGF2BP2 gene associated with T2DM susceptibility by a comprehensive
genetic association research [11]. However, Cui et al. reported no association of the single nucleotide
polymorphisms (SNPs) with diabetes in a Han Chinese population [12]. Moreover, subsequent
replication studies yielded conflicting or inconclusive results [13–16].
The risk allele frequencies of the T2DM susceptible locus are different among populations, for
example distributions of T allele in rs4402960 are 35% in Asians and 30% in Caucasians. In addition,
the insufficient power and small effect of the polymorphisms on T2DM risk may explain to some
degree the inconclusive results. In an effort to arrive at a more definitive conclusion, we conducted
a case-control study to analyze the associations between rs4402960 and rs1470579 of the IGF2BP2 gene
polymorphisms and T2DM in a group of northern Han Chinese subjects followed by a meta-analysis
in the Asian population.
2. Experimental Section
2.1. Study Participants
The present study was conducted in accordance with the Declaration of Helsinki guidelines.
Written informed consents were obtained from all the participants. The study was approved by the
Ethics Committee of Capital Medical University (approval number 2013SY30). In this case-control
study, 461 T2DM-diagnosed patients and 434 controls were recruited at the Jidong Oil Field Hospital
(Hebei, China) from January 2009 to October 2013. The T2DM patients were diagnosed and confirmed
by the American Diabetes Association criteria [17] or had a documented clinical diagnosis of T2DM
from clinical records. The health controls who did not previously diagnosed diabetes, and had fasting
glucose values <5.6 mmol/L without glucose-lowering medications were recruited from the same
area and matched by gender with the cases. Potential participants who had impaired renal function,
malignancies or connective tissue disease were excluded from this study.
2.2. SNPs Genotyping
Genomic DNA was extracted from peripheral white blood cells using blood genome DNA extraction
kits according to the manufacturer’s instructions (BioTeke, Beijing, China). SNPs were genotyped by
matrix assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) using
a Mass ARRAY system (Sequenom, Inc., San Diego, CA, USA). The call rates for the genotyping of
the SNPs were >95%. In order to verify whether there was genotyping error, we randomly selected
40 samples for each SNP, and verified the genotype using Sanger sequencing.
2.3. Data Collection
Data were collected by a comprehensive review of hospital records, including fasting plasma
glucose (FPG), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C),
systolic blood pressure (SBP), diastolic blood pressure (DBP) and uric acid (UA), which were all tested
through standard ways in the clinical laboratory of the Jidong Oil Field Hospital [17]. Weight and
height were measured when the participants were lightly clothed and barefoot. Body mass index (BMI)
was calculated as weight in kilograms divided by the squared of height in meters (kg/m2).
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2.4. Statistical Analysis
Analyses were conducted with SPSS Software V.18.0 (SPSS Inc., Chicago, IL, USA). Continuous
variables were presented as mean ˘ standard deviation (SD). Categorical variables were presented
as numbers and percentages. Student’s t test was used to test between-group differences for
continuous variables. Chi-square test was applied for categorical variables. Gene-disease associations
were measured using odds ratios (ORs), 95% confidence interval (95% CI) and p value derived
from unconditional logistic regression (ULR) analyses adjusted for age, sex and BMI. Individuals
homozygous for the risk allele (R/R), heterozygous (R/r) and homozygous for the non-risk allele (r/r)
were assigned a categorical variable according to genotypes. The dominant model was defined as R/R
+ R/r versus r/r, and the recessive model as R/R versus R/r + r/r.
The Haploview program 4.2 was used to calculate pairwise linkage disequilibrium (LD) statistics
and examine haplotype associations with T2DM. Chi-square test was used to test Hardy-Weinberg
equilibrium (HWE) for genotype frequencies. The significance level was set at p < 0.05 (two-tailed).
2.5. Meta-Analysis
Genetic association studies published before the end of December 2015 were identified through
a search of PubMed, EMBASE, ISI Web of Science, Wanfang and Chinese National Knowledge
Infrastructure (CNKI). The key words of our search included “IGF2BP2”, “T2DM”, “T2D”, rs4402960,
rs1470579. Eligible studies had to meet all of the criteria as follows: (1) in case–control or cohort study
design; (2) detailed allele frequencies and genotype data for rs4402960, rs1470579 with T2DM risk in
Asian populations. The major exclusive criteria:(1) incomplete or duplicate data; (2) meta-analyses
and review articles.
According to the meta-analysis following Observation Studies in Epidemiology (MOOSE)
standards, data were independently extracted from all genetic association studies independently
by two authors [18]. Any disagreement was resolved by discussion with other authors. The items
collected were as follows: the first author, the year of publication, cases and controls numbers, country
of origin, diagnostic criterion, average BMI and age of cases, frequencies of risk allele and genotypes
in cases and controls. The pooled OR and 95% CI were calculated to assess the association between
IGF2BP2 polymorphisms and the risk of T2DM based on the genetic inheritance models described
as before. The Z-test was used to test the significance of the pooled OR. Subgroup analyses were
performed according to the criterion of diagnostic (World Health Organization (WHO) or others),
sample size (case samples <500 or >500), and mean BMI (<25 kg/m2 or 25–30 kg/m2) and age (<55,
55–60 or >60)of cases. Heterogeneity between studies was evaluated with the I2 test and the Q
statistic [19]. I2 > 50% or p < 0.10 for Q statistics was considered as significant heterogeneity. Upon the
existence of heterogeneity, either the random-effect model or fixed-effect model would be adopted.
Sensitivity analyses were performed for the effect of included individual researches and the assessment
of the results stability. Funnel plots represented publication bias graphically [20]. The significance level
was set at p < 0.05 (two-tailed). Analyses were conducted with the Review Manager 5.0 (Cochrane
Collaboration, London, UK).
3. Results
3.1. Case-Control Study
In total, 274 male and 187 female (53.48 ˘ 11.33 years) patients, and 249 male and 185 female
(51.82 ˘ 12.67 years) controls were included in the final analysis. T2DM patients had significantly
higher BMI, FPG, TG, TC, LDL-C, SBP, DBP than health controls (p < 0.05) (Table 1).
In order to verify whether there was genotyping error, PCR and Sanger sequencing were performed
for randomly selected 40 samples. The Sanger sequencing data was consisted with MALDI-TOF MS
sequencing data (Table S1).
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Table 2 listed the genotype and allele frequencies of the rs4402960 and rs1470579 polymorphisms.
The genotypic distribution for each of the SNPs was in agreement with the predicted HWE values in
health control (rs4402960 HW-p = 0.088; rs1470579 HW-p = 0.052). The genotype and allele frequencies
of the rs4402960 and rs1470579 were similar in T2DM and control groups (p > 0.05). In the recessive
model, the carriers of TT at rs4402960 had a higher risk of T2DM compared to the carriers of TG + GG
(adjusted odds ratio (AOR) = 1.962, 95% CI = 1.065–3.612, p = 0.031); the carriers of CC at rs1470579
were more susceptible to T2DM than the carriers of CA + AA (AOR = 2.014, 95% CI = 1.114–3.642,
p = 0.021). There was no statistical significance found in the dominant model of the rs4402960 and
rs1470579 (p > 0.05). The two SNPs are in strong LD (D1 = 1 and r2 = 0.9). There was no statistical
significant association of haplotype with T2DM (Table S2).
Table 1. Demographic information and clinical characteristics of the participants.
Characteristic T2DM Controls p
Gender (male/female) 274/187 249/185 0.53
Age (years) 53.48 ˘ 11.33 51.82 ˘ 12.67 0.039
BMI (kg/m2) 27.05 ˘ 3.96 24.65 ˘ 3.57 <0.001
FPG (mmol/L) 7.26 ˘ 2.49 6.20 ˘ 1.95 <0.001
TG (mmol/L) 2.15 ˘ 1.96 1.63 ˘ 1.19 <0.001
TC (mmol/L) 4.81 ˘ 1.13 4.65 ˘ 0.93 <0.001
LDL-C (mmol/L) 2.79 ˘ 0.75 2.56 ˘ 0.64 <0.001
SBP (mmHg) 141.41 ˘ 20.97 128.33 ˘ 20.92 <0.001
DBP (mmHg) 87.79 ˘ 13.40 81.69 ˘ 13.72 <0.001
UA (mmol/L) 292.95 ˘ 80.69 300.25 ˘ 83.93 0.19
BMI: body mass index; FPG: fasting plasma glucose; TG: triglycerides; TC: total cholesterol; LDL-C: low-density
lipoprotein cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure; UA: uric acid.
Table 2. Genotype and allele frequencies of the SNPs in patients with T2DM and healthy controls.
IGF2BP2
Polymorphisms Cases Controls
Crude Model Adjusted Model *
OR (95% CI) p OR (95% CI) p
rs4402960 n = 457 n = 420
Allele (%)
T 230(25.2) 209 (24.9)
G 914(74.8) 631 (75.1) 1.02 (0.82–1.26) 0.89 1.04 (0.82–1.31) 0.76
Genotype(%)
GG 261 (57.1) 230 (54.8)
TG 162 (35.5) 171 (40.7) 0.84(0.63–1.11) 0.20 0.84 (0.62–1.13) 0.24
TT 34 (7.4) 19 (4.5) 1.58(0.88–2.84) 0.13 1.73 (0.92–3.23) 0.09
Dominant model (%)
GG 261 (57.1) 230 (54.8)
TT + TG 196 (42.9) 190 (45.2) 0.91(0.70–1.19) 0.48 0.93 (0.70–1.24) 0.63
Recessive model (%)
TG + GG 423 (93.6) 401 (95.5)
TT 34 (7.4) 19 (4.5) 1.70 (0.95–3.02) 0.07 1.96 (1.07–3.61) 0.03
rs1470579 n = 459 n = 419
Allele (%)
A 674 (73.4) 621 (74.1)
C 244 (26.6) 217 (25.9) 1.04(0.84–1.28) 0.75 1.05 (0.83–1.31) 0.73
Genotype(%)
AA 253 (55.1) 222 (53)
CA 168 (36.6) 177 (42.2) 0.82(0.63–1.10) 0.19 0.83 (0.62–1.11) 0.21
CC 38 (8.3) 20 (4.8) 1.67 (0.94–2.95) 0.08 1.76 (0.95–3.23) 0.07
Dominant model (%)
AA 253 (55.1) 222 (53)
CC + CA 206 (44.9) 197 (47) 0.92 (0.70–1.20) 0.53 0.93 (0.70–1.23) 0.62
Recessive model (%)
AA + CA 421 (91.7) 399 (95.2)
CC 38 (8.3) 20 (4.8) 1.80 (1.03–3.15) 0.04 2.01 (1.11–3.64) 0.02
* Adjusted for age, sex, BMI.
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3.2. Meta-Analysis
In total, 36 previous studies plus our case-control study were finally included in this meta-analysis.
For the rs4402960, 34 articles were available, including 49,974 cases and 54,315 controls in total. For the
rs1470579, 14 articles involved 23,470 cases and 23,671 controls in total [12,15,21–53] (Table S3; Figure 1).
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The significant associations between rs4402960 polymorphism of IGF2BP2 and susceptibility of
T2DM were found in the allele comparison, genetic models of dominant and recessive(OR = 1.16,
95% CI = 1.13–1.19, p = 10´5; OR = 1.19, 95% CI = 1.15–1.24, p = 10´5; OR = 1.24, 95% CI = 1.17–1.32,
p = 10´5, respectively). In the stratified analysis by ethnicity, significantly increased risks were found
among Chinese and Japanese populations (p < 0.05). However, no significant associations were found
in Indian and Korean populations under the recessive model and among other ethnic populations
(p > 0.05). In the stratified analysis by diagnostic criterion, sample size and average age and BMI of
cases, significant associations were identified for rs4402960 in all genetic models (Table 3).
For the association between susceptibility of T2DM and rs1470579 polymorphism, the pooled
per-allele OR of the C variant for T2DM was 1.14 (95% CI = 1.11–1.18, p = 10´5), with corresponding
results under dominant and recessive genetic models of 1.11 (95% CI = 1.03–1.19, p = 4 ˆ 10´3) and
1.21 (95% CI = 1.09–1.36, p = 6 ˆ 10´4), respectively. In the stratified analysis by ethnicity, significantly
increased risks were found among Chinese and Japanese populations (p < 0.05). No significant
associations were found in the Indian populations (p > 0.05). C allele of rs1470579 was also associated
with increased T2DM risk, when studies were stratified for diagnostic criterion, size of sample and
average BMI of cases (p < 0.05). However, under the dominant model, no significant association
was found in the “others” of diagnostic criterion, case samples <500 and 25 ď BMI ď 30 subgroups
(p > 0.05). Under the recessive model, no significant association was found in the 25 ď BMI ď 30
subgroup (p > 0.05). Upon the research stratification for average age of cases, significant association
was not detected in the age <55 subgroup in all genetic models of rs1470579 (p > 0.05) (Table 4).
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Table 3. Results of meta-analysis for IGF2BP2 rs4402960 polymorphism and T2DM.
Overall and
Subgroup
Number of
Studies
T Allele Number of
Studies
Dominant Model Number of
Studies
Recessive Model
OR (95% CI) p(Z) p(Q) OR (95% CI) p(Z) p(Q) OR (95% CI) p(Z) p(Q)
All 40 1.16 (1.13–1.19) 10´5 0.04 22 1.19 (1.15–1.24) 10´5 0.59 22 1.24 (1.17–1.32) 10´5 0.53
Ethnicity
Chinese 20 1.15 (1.1–1.2) 10´5 0.01 9 1.16 (1.08–1.25) 10´4 0.35 9 1.28 (1.16–1.41) 10´5 0.4
Japanese 10 1.18 (1.14–1.23) 10´5 0.57 9 1.21 (1.15–1.28) 10´5 0.93 9 1.24 (1.14–1.35) 10´5 0.34
Korean 2 1.15 (1.08–1.23) 10´5 0.69 2 1.17 (1.07–1.27) 7 ˆ 10´4 0.74 2 1.16 (0.98–1.36) 0.08 0.76
Indian 5 1.17 (1.08–1.27) 10´5 0.74 2 1.31 (1.09–1.58) 4 ˆ 10´3 0.52 2 1.11 (0.91–1.36) 0.29 0.98
others 3 1.09 (0.99–1.21) 0.09 0.48
Diagnostic criterion
WHO 24 1.15 (1.11–1.19) 10´5 0.008 15 1.19 (1.15–1.24) 10´5 0.75 15 1.25 (1.17–1.33) 10´5 0.36
Others 15 1.17 (1.13–1.21) 10´5 0.57 7 1.18 (1.05–1.33) 6 ˆ 10´3 0.19 7 1.24 (1.07–1.42) 0.003 0.59
Sample size
<500 9 1.1 (1.02–1.18) 0.01 0.55 5 1.11 (1.01–1.4) 0.04 0.5 5 1.48 (1.14–1.92) 0.003 0.59
>500 30 1.16 (1.13–1.19) 10´5 0.01 18 1.2 (1.16–1.25) 10´5 0.67 17 1.23 (1.16–1.31) 10´5 0.5
Mean BMI of cases
<25 10 1.21 (1.16–1.27) 10´5 0.41 8 1.21 (1.14–1.3) 10´5 0.88 8 1.31 (1.17–1.46) 10´5 0.44
25–30 22 1.16 (1.13–1.19) 10´5 0.69 13 1.18 (1.13–1.24) 10´5 0.2 13 1.25 (1.14–1.36) 10´5 0.54
Mean age of cases
<55 10 1.15 (1.1–1.2) 10´5 0.51 7 1.18 (1.1–1.28) 10´4 0.26 7 1.17 (1.03–1.32) 0.02 0.71
55–60 12 1.2 (1.15–1.24) 10´5 0.33 5 1.21 (1.13–1.29) 10´5 0.42 5 1.41 (1.24–1.61) 10´5 0.43
>60 12 1.16 (1.12–1.2) 10´5 0.42 10 1.19 (1.13–1.25) 10´5 0.6 10 1.22 (1.12–1.32) 10´5 0.6
p(Z): Z test used to determine the significance of the overall OR; p(Q): Cochran’s chi-square Q statistic test used to assess the heterogeneity in subgroups.
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Table 4. Results of meta-analysis for IGF2BP2 rs1470579 polymorphism and T2DM.
Overall and
Subgroup
Number of
Studies
C Allele Number of
Studies
Dominant Model Number of
Studies
Recessive Model
OR (95% CI) p(Z) p(Q) OR (95% CI) p(Z) p(Q) OR (95% CI) p(Z) p(Q)
All 16 1.14 (1.11–1.18) 10´5 0.65 8 1.11 (1.03–1.19) 0.004 0.09 8 1.21 (1.09–1.36) 6 ˆ 10´4 0.05
Ethnicity
Chinese 9 1.11 (1.06–1.16) 10´5 0.63 4 1.04 (0.93–1.16) 0.45 0.16 4 1.14 (0.92–1.4) 0.23 0.25
Japanese 6 1.17 (1.13–1.21) 10´5 0.73 3 1.16 (1.04–1.28) 5 ˆ 10´3 0.09 3 1.31 (1.12–1.53) 6 ˆ 10´4 0.02
Indian 1 1.10 (0.95–1.28) 0.2 NA 1 1.19 (0.93–1.52) 0.16 NA 1 1.1 (0.86–1.4) 0.45 NA
Diagnostic criterion
WHO 9 1.14 (1.1–1.18) 10´5 0.6 4 1.15 (1.06–1.25) 9 ˆ 10´4 0.11 4 1.17 (1.03–1.34) 0.02 0.16
Others 7 1.15 (1.09–1.21) 10´5 0.43 4 0.99 (0.86–1.15) 0.94 0.36 4 1.3 (1.07–1.58) 0.008 0.05
Sample size
<500 5 1.17 (1.06–1.29) 0.002 0.25 4 1.01 (0.86–1.17) 0.97 0.1 4 1.57 (1.19–2.08) 0.001 0.22
>500 11 1.14 (1.11–1.17) 10´5 0.74 4 1.14 (1.05–1.23) 0.001 0.27 4 1.16 (1.02–1.3) 0.02 0.15
Mean BMI of cases
<25 6 1.17 (1.13–1.21) 10´5 0.73 3 1.16 (1.04–1.28) 0.005 0.09 3 1.31 (1.12–1.53) 6 ˆ 10´4 0.02
25–30 9 1.11 (1.06–1.16) 10´5 0.62 5 1.07 (0.96–1.18) 0.21 0.19 5 1.12 (0.96–1.31) 0.16 0.39
Mean age of cases
<55 3 1.11 (0.99–1.24) 0.08 0.34 3 1.14 (0.97–1.33) 0.12 0.08 3 1.19 (0.97–1.47) 0.1 0.28
55–60 4 1.16 (1.09–1.24) 10´5 0.54 1 0.88 (0.68–1.15) 0.36 NA 1 1.93 (1.26–2.95) 0.002 NA
>60 8 1.14 (1.11–1.18) 10´5 0.39 4 1.13 (1.04–1.23) 0.005 0.23 4 1.16 (1.01–1.34) 0.03 0.09
p(Z): Z test used to determine the significance of the overall OR; p(Q): Cochran’s chi-square Q statistic test used to assess the heterogeneity in subgroups. NA: not available.
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Significant heterogeneity was observed for the rs4402960 polymorphism in allele contrast genetic
model and for the rs1470579 polymorphism in dominant and recessive genetic models. Thus, the
calculation of the pooled OR was based on a random-effects model. A sensitivity analysis was
conducted to explore the sources of heterogeneity, when the number of studies ě10. There was no
single research that affected the pooled OR and CIs in a qualitative way. The funnel plot revealed no
obvious publication bias (Figures S1 and S2).
4. Discussion
The associations between IGF2BP2 polymorphism and T2DM risk have been well investigated in
several studies, while the association remained unclear. In this study, we validated the associations
in a northern Han Chinese population. Our case-control study showed that rs4402960 and rs1470579
polymorphism associated with risk of T2DM under the recessive genetic models (p < 0.05), with no
statistical significance in other models.
When it comes to the problem of small sample sizes and insufficient statistical power,
Meta-analysis was usually performed in terms of genetic association studies of complicated
diseases [54]. Therefore, for the further investigation of the influence of the rs4402960 and rs1470579
polymorphisms on T2DM risk, a meta-analysis of 36 publications in the Asians has been conducted
with the results of case-control study. As far as we know, this is the first quantitative meta-analysis
to date investigating the association between the two SNPs of IGF2BP2 and T2DM risk in the Asians.
The results of meta-analysis revealed that rs4402960 and rs1470579 was significantly associated with
susceptibility of T2DM in Asians. Considering small deviation from different genetic models of
IGF2BP2 polymorphism, we investigated the associations of the two SNPs with T2DM risk based on
dominant and recessive models and also found a significant result [55]. The significant associations
of IGF2BP2 polymorphism and T2DM were only found under the recessive genetic models, which
could be caused by the small affected genotypes and insufficient statistical power in some models.
In addition, some studies showed an association of the IGF2BP2 variant with T2DM under the
recessive model [26,40], while others found the under the dominant genetic model [27,34,37,51,56].
Complex diseases such as T2DM are multifactorial and polygenic, and it is generally assumed that
each of the factors and genes contribute a small amount to phenotypic variability. In addition, genetic
heterogeneity is common for complex traits, referring to the presence of a variety of genetic defects that
cause the same disease in clinical settings. Therefore, the polygenic etiology and genetic heterogeneity
may partly explained the inconsistent associations between IGF2BP2 (rs4402960 and rs1470579) and
T2DM under various models and different populations.
In the stratified analysis by ethnicity, statistically significant associations were found in Chinese
and Japanese for the rs4402960 and rs1470579 polymorphisms in all genetic models. However, we
observed that association between rs4402960 polymorphism and risk for T2DM susceptibility in
Japanese populations (OR = 1.18) was stronger than that in Chinese (OR = 1.15). Such result may be
due to ethnic differences, since the frequency of T allele in rs4402960 is 0.239 in Chinese, while 0.298
in Japanese. Similar results were also found in rs1470579 polymorphism. No significant associations
found in other ethnic populations could be explained by study design or the limited number of studies
which had insufficient statistical power to detect a slight effect. The more researches are needed to
examine the effect of this variation on T2DM in different ethnic populations.
As for the subgroup analysis based on diagnostic criterion, size of sample and average and BMI of
cases, significant associations between rs4402960 and T2DM were consisted among all genetic models.
The large studies usually dominate the meta-analysis, while the effect of studies with small sample
is apparently decreased [57]. In our research, “T” allele in rs4402960 was significantly associated
with T2DM risk in both case samples <500 and >500 subgroup. Obesity is an key factor in the onset
and progression of insulin resistance and T2DM [58]. It is well known that T2DM and obesity have
a genetic basis [59]. Previous studies also have reported significant associations of rs4402960 with
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obesity [60–62]. But we found significant association in both BMI < 25 kg/m2 and 25–30 kg/m2 studies,
suggesting that rs4402960 is an associated factor for T2DM independent of obesity.
For rs1470579, the study showed inconsistent association and significant heterogeneity among
the stratified analysis, might resulting from the limited amount of studies available. Older age is
risk factor for T2DM [4]. The effect conferred by the risk allele changed with aging [21]. We found
rs1470579 significantly associated with T2DM in the mean age >60 studies, while no association existed
in the mean age <55. There may be interaction between age and IGF2BP2. The association needs to be
verified in more studies with larger sample size and prospective study in the future.
IGF2BP2, a significant signaling molecule for growth and insulin, has been found have effect
on pancreatic development in animal models [63,64]. Huang et al. stated that the higher levels
of FPG, postprandial serum insulin and TC were founded among T2DM patients who carried
the C allele of rs1470579 compared with AA carriers [27]. Rs4402960 attenuate the first phase of
glucose-stimulated insulin secretion based on hyperglycaemic clamps [10]. Similar results were
also observed in subsequent studies in other populations [25,65,66]. Thus, it could be said that the
polymorphism IGF2BP2 play role in the regulation of pancreatic beta-cell function [27]. Since the
location of the two SNPs is the region of 50-kb of intron 2, it can be hypothesized that the effect
of diabetes-predisposing variants can be exerted on the expression regulation of IGF2BP2 [7].
Besides, SNPs could be linked to nearby variants that have a role on larger non-coding transcripts,
microRNAs and so on [9]. In addition, rs4402960 and rs1470579 may be a proxy marker rather
than a true functional variant. The diacylglycerol kinase g-1 (DGKG) located closed to IGF2BP2, has
been reported associated with metabolic regulation [67]. Therefore, further functional studies of
pathophysiological mechanisms IGF2BP2 are warranted.
Some limitations still existed in the present analysis. Firstly, the study is based on the design
of case-control, which restricted the cause-effect inference. The cohort studies are required for the
further consequence confirmation. Secondly, only the sample size and allele frequency were available
in some of the included studies. Therefore we exhibited the wt/mutant allele numbers in cases and
controls in the pooled data, instead of the genotype information. Thirdly, there was still heterogeneity
in the subgroup analysis. The more confounding factors should be considering. Fourthly, numerous
environmental, genetic factors and the interactions among these factors contribute to the progression
of T2DM. Our meta-analysis results did not adjust any confounding covariant, for example gender,
drinking status, smoking habit. A more comprehensive analysis should be conducted when more
original information is available and interactions among the risk factors are considered.
5. Conclusions
In conclusion, we detected the genetic susceptibility of IGF2BP2 on T2DM under different genetic
models, and we confirmed the association between rs4402960 and rs1470579 (IGF2BP2) and T2DM
under the recessive model in a northern Han Chinese population. Meta-analysis indicated significant
contributions of IGF2BP2 gene rs4402960 and rs1470579 polymorphisms to T2DM in Asian populations.
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